Menu
Recruiting NCT04929912

Electroporation for Cancer Treatment Real World Registry

— Observational Skin Cancer Gastrointestinal Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Skin Cancer, Gastrointestinal Cancer. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United Kingdom
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This registry aims to assess real-world long-term disease outcomes for patients treated using reversible electroporation and a chemotherapeutic or calcium; in particular tumour response rates and recurrence rates. The study also aims to characterise side effects and the occurrence of Adverse Events and their relationship to the treatment.

Primary outcome measures

  • Incidence of Treatment-Emergent Adverse Events (CTCAE) [Time frame: 5 years]
Secondary outcome measures (1)
  • Response Evaluation Criteria in Solid Tumours (RECIST) [Time frame: 3 months, 12 months, 3 years, 5 years]

Eligibility criteria

Inclusion criteria

  • Any patient who has been treated using Calcium Electroporation
  • Any patient who has been treated using Electrochemotherapy
  • Patients must be mentally capable of understanding the information given
  • Patients must give written informed consent.

Exclusion criteria

  • None

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

United Kingdom · 1 center
  • Royal London Hospital — London

Identifiers

NCT: NCT04929912 · CIP-21-001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗